Myriad Genetics Inc. (Nasdaq: MYGN) published data in the Journal of Urology demonstrating the accuracy of its Prolaris test in predicting metastases in prostate cancer. The stock price soared $3.59 to close at $35.03.
Myriad Genetics Demonstrates Prolarsis Accuracy
February 18, 2014 at 16:23 PM EST
